HANMI PHARM. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 318,500 KRW | -0.16% |
|
-0.31% | -9.65% |
| 05-08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
| 05-01 | Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8% | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,490,741 | 4,397,245 | 3,373,870 | 3,711,167 | 4,473,421 | 4,041,166 | - | - |
| Enterprise Value (EV) 2 | 4,184 | 5,040 | 3,855 | 4,231 | 4,473 | 4,323 | 4,077 | 3,909 |
| P/E ratio | 65.7 x | 368 x | 50.3 x | 36.5 x | 30.6 x | 23.1 x | 20.9 x | 18.7 x |
| Yield | 0.17% | 0.14% | 0.18% | 0.17% | - | 0.16% | 0.16% | 0.16% |
| Capitalization / Revenue | 3.13 x | 4.09 x | 2.8 x | 2.79 x | 3 x | 2.48 x | 2.29 x | 2.3 x |
| EV / Revenue | 3.76 x | 4.68 x | 3.2 x | 3.18 x | 3 x | 2.66 x | 2.31 x | 2.23 x |
| EV / EBITDA | 26.3 x | 45.7 x | 18 x | 16.6 x | 14 x | 12.4 x | 11.1 x | 9.84 x |
| EV / FCF | -27.2 x | 45.9 x | 21.2 x | 32.1 x | - | 21.8 x | 19.7 x | 18.1 x |
| FCF Yield | -3.67% | 2.18% | 4.72% | 3.12% | - | 4.58% | 5.08% | 5.52% |
| Price to Book | 4.73 x | 6.02 x | 4.2 x | 4.26 x | - | 3.67 x | 3.13 x | 2.77 x |
| Nbr of stocks (in thousands) | 12,744 | 12,732 | 12,718 | 12,703 | 12,691 | 12,688 | - | - |
| Reference price 3 | 273,920 | 345,361 | 265,283 | 292,157 | 352,500 | 318,500 | 318,500 | 318,500 |
| Announcement Date | 20-02-07 | 21-02-04 | 22-01-27 | 23-02-08 | 24-02-02 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,114 | 1,076 | 1,206 | 1,332 | 1,491 | 1,628 | 1,762 | 1,756 |
| EBITDA 1 | 159.3 | 110.3 | 214.5 | 254.9 | 319.1 | 348.2 | 367.8 | 397.3 |
| EBIT 1 | 103.9 | 48.68 | 127.4 | 157 | 220.7 | 255.8 | 275.4 | 310.6 |
| Operating Margin | 9.33% | 4.52% | 10.56% | 11.79% | 14.8% | 15.71% | 15.64% | 17.69% |
| Earnings before Tax (EBT) 1 | 83.3 | 22.13 | 103.8 | 116.9 | 194 | 233.6 | 261.4 | 294.5 |
| Net income 1 | 52.11 | 11.96 | 81.08 | 76.93 | 159.3 | 174.6 | 190.8 | 217.8 |
| Net margin | 4.68% | 1.11% | 6.72% | 5.78% | 10.68% | 10.72% | 10.83% | 12.4% |
| EPS 2 | 4,170 | 939.5 | 5,270 | 7,994 | 11,522 | 13,768 | 15,214 | 17,053 |
| Free Cash Flow 3 | -153,685 | 109,719 | 181,974 | 131,890 | - | 198,155 | 207,125 | 215,967 |
| FCF margin | -13,800.71% | 10,198.36% | 15,088.37% | 9,903.76% | - | 12,173.85% | 11,757.53% | 12,301.24% |
| FCF Conversion (EBITDA) | - | 99,459.77% | 84,835.58% | 51,735.49% | - | 56,909.74% | 56,313.36% | 54,364.06% |
| FCF Conversion (Net income) | - | 917,443.51% | 224,446.95% | 171,451.1% | - | 113,523.09% | 108,584.53% | 99,168.37% |
| Dividend per Share 2 | 461.9 | 471.2 | 480.6 | 490.2 | - | 495.0 | 501.0 | 499.1 |
| Announcement Date | 20-02-07 | 21-02-04 | 22-01-27 | 23-02-08 | 24-02-02 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 303.1 | 350.5 | 321.1 | 316.5 | 342.1 | 351.3 | 361.7 | 342.7 | 364.6 | 422.4 | 403.7 | 386.1 | 399.8 | 439.6 | 422.5 |
| EBITDA 1 | - | - | - | 54.47 | 72.67 | 64.1 | 84.57 | 57.83 | - | 94.72 | 94.8 | 74.1 | 85.6 | 74.3 | - |
| EBIT 1 | 36.88 | 42.72 | 38.67 | 29.57 | 46.8 | 37.76 | 60.45 | 33.16 | 57.52 | 70.1 | 76.64 | 50.59 | 58.86 | 68.59 | 70.05 |
| Operating Margin | 12.17% | 12.19% | 12.04% | 9.34% | 13.68% | 10.75% | 16.71% | 9.67% | 15.78% | 16.6% | 18.99% | 13.1% | 14.72% | 15.6% | 16.58% |
| Earnings before Tax (EBT) 1 | 32.12 | 34.14 | 35.67 | 26.41 | 37.89 | 16.6 | 55.62 | 25.43 | 56.28 | 56.91 | 74.98 | 51.7 | 48.6 | 59.8 | 72.05 |
| Net income 1 | 23.4 | 17.47 | 19.31 | 18.02 | 25.37 | 13.61 | 43.11 | 16.06 | 54.71 | 47.45 | 55 | 38.2 | 32 | 41.8 | 37.7 |
| Net margin | 7.72% | 4.98% | 6.01% | 5.69% | 7.42% | 3.87% | 11.92% | 4.68% | 15% | 11.23% | 13.63% | 9.89% | 8% | 9.51% | 8.92% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-04 | 22-01-27 | 22-04-27 | 22-07-18 | 22-11-01 | 23-02-08 | 23-04-26 | 23-07-28 | 23-11-01 | 24-02-02 | 24-04-30 | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 693 | 643 | 481 | 519 | - | 282 | 36.1 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 132 |
| Leverage (Debt/EBITDA) | 4.354 x | 5.825 x | 2.244 x | 2.038 x | - | 0.8109 x | 0.0981 x | - |
| Free Cash Flow 2 | -153,685 | 109,719 | 181,974 | 131,890 | - | 198,155 | 207,125 | 215,967 |
| ROE (net income / shareholders' equity) | 7.93% | 1.65% | 9.21% | 9.89% | 15.1% | 17.1% | 15.5% | 16.3% |
| ROA (Net income/ Total Assets) | 3.54% | 0.63% | 3.51% | 4.29% | - | 9.68% | 9.54% | 10.1% |
| Assets 1 | 1,471 | 1,898 | 2,310 | 1,794 | - | 1,803 | 1,999 | 2,148 |
| Book Value Per Share 3 | 57,930 | 57,329 | 63,128 | 68,632 | - | 86,889 | 101,860 | 114,836 |
| Cash Flow per Share 3 | 996.0 | 11,901 | 15,876 | 12,773 | - | 23,752 | 24,556 | 27,291 |
| Capex 1 | 166 | 41.8 | 19.9 | 30.4 | - | 48.4 | 59.9 | 55.8 |
| Capex / Sales | 14.92% | 3.89% | 1.65% | 2.28% | - | 2.97% | 3.4% | 3.18% |
| Announcement Date | 20-02-07 | 21-02-04 | 22-01-27 | 23-02-08 | 24-02-02 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
318,500
KRW
Average target price
411,162
KRW
Spread / Average Target
+29.09%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.65% | 2.95B | |
| +19.62% | 43.27B | |
| +24.52% | 22.92B | |
| +20.29% | 15.43B | |
| +7.48% | 12.95B | |
| +42.51% | 11.83B | |
| -8.84% | 6.91B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.13% | 5.55B |
- Stock Market
- Equities
- A128940 Stock
- Financials Hanmi Pharm. Co., Ltd.
